KRAS and cancer: Given that single drugs elicit limited antitumour responses in KRAS-mutated cancers, in part due to resistance mechanisms, this study proposes the combination of JAK2i with the recently FDA-approved KRASG12Ci Sotorasib based on a notable synergistic effect in vitro and in vivo.